oncology » Trang Công Nghệ | Trangcongnghe.vn

Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Globe Newswire

Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Globenewswire -

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Globe Newswire

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Globenewswire -

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

Globe Newswire

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

Globenewswire -

Curium Announces Definitive Agreement to Merge with Lantheus

Globe Newswire

Curium Announces Definitive Agreement to Merge with Lantheus

Globenewswire -

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

Globe Newswire

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

Globenewswire -

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Globe Newswire

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Globenewswire -

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Globe Newswire

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Globenewswire -

XEM THÊM TIN MỚI